{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T21:07:02Z","timestamp":1789247222208,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40121-026-01400-w","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:25:49Z","timestamp":1784870749000},"page":"2609-2625","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Older Adults in the Netherlands"],"prefix":"10.1007","volume":"15","author":[{"given":"Annefleur C.","family":"Langedijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris","family":"van den Dungen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits M. E.","family":"Franssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Goeijenbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahuva","family":"Averin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Atwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1672-4906","authenticated-orcid":false,"given":"Diana","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"issue":"4","key":"1400_CR1","doi-asserted-by":"publisher","first-page":"2002688","DOI":"10.1183\/13993003.02688-2020","volume":"57","author":"K Korsten","year":"2021","unstructured":"Korsten K, Adriaenssens N, Coenen S, et al. Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study. Eur Respir J. 2021;57(4):2002688.","journal-title":"Eur Respir J"},{"key":"1400_CR2","unstructured":"National Institute for Public Health and the Environment: Ministry of Health W, and Sport. Respiratory syncytial virus (RSV) 2024. Available from: https:\/\/www.rivm.nl\/en\/rsv#:~:text=RSV%20is%20common%20in%20the%20Netherlands,%20especially%20in"},{"issue":"Suppl 1","key":"1400_CR3","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1093\/infdis\/jiac150","volume":"226","author":"CK Johannesen","year":"2022","unstructured":"Johannesen CK, van Wijhe M, Tong S, et al. Age-specific estimates of respiratory syncytial virus-associated hospitalizations in 6 European countries: a time series analysis. J Infect Dis. 2022;226(Suppl 1):S29-s37.","journal-title":"J Infect Dis"},{"key":"1400_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101227","volume":"51","author":"CK Johannesen","year":"2025","unstructured":"Johannesen CK, Gideonse D, Osei-Yeboah R, et al. Estimation of respiratory syncytial virus-associated hospital admissions in five European countries: a modeling study. The Lancet Regional Health - Europe. 2025;51:101227.","journal-title":"The Lancet Regional Health - Europe"},{"issue":"16","key":"1400_CR5","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","volume":"388","author":"EE Walsh","year":"2023","unstructured":"Walsh EE, P\u00e9rez Marc G, Zareba AM, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023;388(16):1465\u201377.","journal-title":"N Engl J Med"},{"key":"1400_CR6","unstructured":"Abrysvo: European Medicines Agency (EMA); 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abrysvo"},{"key":"1400_CR7","unstructured":"Health Council of the Netherlands. Health Council 2025 Vaccination Advisory Agenda. 2025."},{"key":"1400_CR8","doi-asserted-by":"crossref","unstructured":"Li X, Willem L, Johannesen CK, et al. Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: A multi-country analysis. medRxiv. 2024:2024.08.06.24311440.","DOI":"10.1101\/2024.08.06.24311440"},{"key":"1400_CR9","doi-asserted-by":"crossref","unstructured":"Zeevat F, Luttjeboer J, Korsten K, et al. Evaluating cost-effectiveness of RSV vaccination strategies for older adults in the Netherlands. Vaccine. 2025 2025\/10\/24\/;65:127735.","DOI":"10.1016\/j.vaccine.2025.127735"},{"key":"1400_CR10","unstructured":"Zeevat F, Luttjeboer J, Paulissen JHJ, et al. Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United Kingdom. The Journal of Infectious Diseases. 2021."},{"issue":"1","key":"1400_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14760584.2024.2436183","volume":"24","author":"A Averin","year":"2025","unstructured":"Averin A, Huebbe B, Atwood M, et al. Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany. Expert Rev Vaccines. 2025;24(1):1\u201310.","journal-title":"Expert Rev Vaccines"},{"key":"1400_CR12","unstructured":"Central Bureau of Statistics. Population pyramid. 2023. https:\/\/www.cbs.nl\/nl-nl\/visualisaties\/dashboard-bevolking\/bevolkingspiramide."},{"key":"1400_CR13","doi-asserted-by":"crossref","unstructured":"Meijboom MJ, Pouwels KB, Luytjes W, et al. RSV vaccine in development: Assessing the potential cost-effectiveness in the Dutch elderly population. Vaccine. 2013 2013\/12\/16\/;31(52):6254\u20136260.","DOI":"10.1016\/j.vaccine.2013.10.023"},{"key":"1400_CR14","unstructured":"National Institute for Public Health and the Environment: Ministry of Health W, and Sport. Who is the flu shot for? 2024. https:\/\/www.rivm.nl\/griep-griepprik\/griepprik\/voor-wie-is-griepprik"},{"key":"1400_CR15","unstructured":"Laarman, C., Vanhommerig, J., Summeren, J. van, Hooiveld, M., Meijer, A., Teirlinck, A., Stelma, F. Respiratory syncytial virus (RSV) associated primary care incidence estimates in adults aged 50 years and older in the Netherlands; 2016\u20132019. Utrecht: Nivel, 2024."},{"key":"1400_CR16","doi-asserted-by":"publisher","DOI":"10.17576\/ijphr.1302.2023.02.02","author":"National Institute for Public Health and the Environment: Ministry of Health W, and Sport","year":"2025","unstructured":"National Institute for Public Health and the Environment: Ministry of Health W, and Sport. Methodology of National Health and Morbidity Study (NHMS): adolescent health, Malaysia 2022. Int J Publ Health Res. 2025. https:\/\/doi.org\/10.17576\/ijphr.1302.2023.02.02.","journal-title":"Int J Publ Health Res"},{"issue":"5","key":"1400_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/irv.70107","volume":"19","author":"K Korsten","year":"2025","unstructured":"Korsten K, Welkers MRA, van de Laar T, et al. Unveiling the spectrum of respiratory syncytial virus disease in adults: from community to hospital. Influenza Other Respir Viruses. 2025;19(5):e70107.","journal-title":"Influenza Other Respir Viruses"},{"key":"1400_CR18","doi-asserted-by":"crossref","unstructured":"Averin A, Shaff M, Weycker D, et al. Mortality and readmission in the year following hospitalization for pneumonia among US adults. Respiratory Medicine. 2021 2021\/08\/01\/;185:106476.","DOI":"10.1016\/j.rmed.2021.106476"},{"key":"1400_CR19","unstructured":"Central Bureau of Statistics. Mortality. 2024. https:\/\/www.cbs.nl\/en-gb\/visualisations\/dashboard-population\/population-dynamics\/mortality."},{"key":"1400_CR20","doi-asserted-by":"publisher","unstructured":"Tartof SY, Aliabadi N, Zasowski E, et al. Bivalent RSVpreF effectiveness against RSV-associated hospital or emergency department care over two seasons: a retrospective test-negative case control study. Lancet Reg Health Am. 2026;60:101520. https:\/\/doi.org\/10.1016\/j.lana.2026.101520.","DOI":"10.1016\/j.lana.2026.101520"},{"key":"1400_CR21","unstructured":"Pfizer Inc., Data on File."},{"key":"1400_CR22","doi-asserted-by":"crossref","unstructured":"Rozenbaum MH, Mangen M-JJ, Huijts SM, et al. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis. Vaccine. 2015 2015\/06\/22\/;33(28):3193\u20133199.","DOI":"10.1016\/j.vaccine.2015.05.001"},{"key":"1400_CR23","unstructured":"Consumer price index 2015 = 100 [Internet]. 2024. https:\/\/opendata.cbs.nl\/#\/CBS\/nl\/dataset\/83131NED\/table."},{"issue":"Supplement_1","key":"1400_CR24","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1093\/infdis\/jiac069","volume":"226","author":"Z Mao","year":"2022","unstructured":"Mao Z, Li X, Korsten K, et al. Economic burden and health-related quality of life of respiratory syncytial virus and influenza infection in European community-dwelling older adults. J Infect Dis. 2022;226(Supplement_1):S87\u201394.","journal-title":"J Infect Dis"},{"issue":"11","key":"1400_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187477","volume":"12","author":"TA Kanters","year":"2017","unstructured":"Kanters TA, Bouwmans CAM, van der Linden N, et al. Update of the Dutch manual for costing studies in health care. PLoS ONE. 2017;12(11):e0187477.","journal-title":"PLoS ONE"},{"key":"1400_CR26","unstructured":"G-standaard (Dutch Pricing List). October 2025."},{"key":"1400_CR27","unstructured":"National Flu Prevention Program. Reimbursement. 2025."},{"key":"1400_CR28","unstructured":"Central Bureau of Statistics. Netherlands: Employment rate. 2024. https:\/\/tradingeconomics.com\/netherlands\/employment-rate-females-eurostat-data.html#:~:text=Netherlands%20%2D%20Employment%20rate%3A%20Females%20was,EUROSTAT%20on%20November%20of%202023."},{"key":"1400_CR29","unstructured":"Central Bureau of Statistics. Hourly wage. 2024. https:\/\/www.cbs.nl\/nl-nl\/visualisaties\/dashboard-arbeidsmarkt\/ontwikkeling-cao-lonen\/uurloon."},{"issue":"4","key":"1400_CR30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jval.2010.10.029","volume":"14","author":"R Ara","year":"2011","unstructured":"Ara R, Brazier JE. Using Health State Utility Values from the General Population to Approximate Baselines in Decision Analytic Models when Condition-Specific Data are Not Available. Value Health. 2011;14(4):539\u201345.","journal-title":"Value Health"},{"issue":"1","key":"1400_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/irv.12903","volume":"16","author":"AR Falsey","year":"2022","unstructured":"Falsey AR, Walsh EE, Osborne RH, et al. Comparative assessment of reported symptoms of influenza, respiratory syncytial virus, and human metapneumovirus infection during hospitalization and post-discharge assessed by Respiratory Intensity and Impact Questionnaire. Influenza Other Respir Viruses. 2022;16(1):79\u201389.","journal-title":"Influenza Other Respir Viruses"},{"key":"1400_CR32","unstructured":"Heins M, Korevaar J, Knottnerus B, et al. Monitor Vaccinatiegraad Nationaal Programma Grieppreventie (NPG) 2021. 2022."},{"key":"1400_CR33","unstructured":"Public Health England. Seasonal flu vaccine uptake in GP patients: monthly data, 2018 to 2019. 2019."},{"key":"1400_CR34","unstructured":"Dutch National Healthcare Institute. Guideline for economic evaluations in healthcare (2024 version). 2024."},{"key":"1400_CR35","doi-asserted-by":"crossref","unstructured":"Surie D, Self WH, Yuengling KA, et al. RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons. JAMA. 2025.","DOI":"10.1093\/ofid\/ofaf695.060"},{"key":"1400_CR36","unstructured":"Lassen MCH, Johansen ND, Christensen SH, et al. RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults. N Engl J Med. 2025 Aug 30."},{"key":"1400_CR37","unstructured":"Klein N, editor Effectiveness of RSV Vaccines in Older Adults in the United States, VISION Network, 2023\u20132025. IDWeek 2025; 2025; Atlanta, GA."},{"key":"1400_CR38","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.6355","author":"KL Bajema","year":"2025","unstructured":"Bajema KL, Bui DP, Yan L, et al. Durability of respiratory syncytial virus vaccine effectiveness among US veterans. JAMA Intern Med. 2025. https:\/\/doi.org\/10.1001\/jamainternmed.2025.6355.","journal-title":"JAMA Intern Med"},{"key":"1400_CR39","unstructured":"Melgar M. ACIP Adult RSV Work Group Considerations. Meeting of the ACIP; Atlanta, GA2022."},{"key":"1400_CR40","doi-asserted-by":"crossref","unstructured":"Burkart K, Liang C, Rafferty Q, et al. Respiratory syncytial virus-attributable hospitalizations among adults in high- and middle-income countries: application of the Global Burden of Disease framework. eClinicalMedicine. 2025 2025\/07\/01\/;85:103292.","DOI":"10.1016\/j.eclinm.2025.103292"},{"issue":"4","key":"1400_CR41","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s40121-023-00792-3","volume":"12","author":"Y Li","year":"2023","unstructured":"Li Y, Kulkarni D, Begier E, et al. Adjusting for case under-ascertainment in estimating RSV hospitalisation burden of older adults in high-income countries: a systematic review and modeling study. Infectious Diseases and Therapy. 2023;12(4):1137\u201349.","journal-title":"Infectious Diseases and Therapy"},{"key":"1400_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac300","author":"JM McLaughlin","year":"2022","unstructured":"McLaughlin JM, Khan F, Begier E, et al. Rates of medically attended RSV among US adults: a systematic review and meta-analysis. Open Forum Infect Dis. 2022. https:\/\/doi.org\/10.1093\/ofid\/ofac300.","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"1400_CR43","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s40121-023-00805-1","volume":"12","author":"J Ramirez","year":"2023","unstructured":"Ramirez J, Carrico R, Wilde A, et al. Diagnosis of respiratory syncytial virus in adults substantially increases when adding sputum, saliva, and serology testing to nasopharyngeal swab RT-PCR. Infectious Diseases and Therapy. 2023;12(6):1593\u2013603.","journal-title":"Infectious Diseases and Therapy"},{"issue":"6","key":"1400_CR44","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s40121-023-00802-4","volume":"12","author":"MH Rozenbaum","year":"2023","unstructured":"Rozenbaum MH, Begier E, Kurosky SK, et al. Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of Current Data. Infect Dis Ther. 2023;12(6):1487\u2013504.","journal-title":"Infect Dis Ther"},{"issue":"2","key":"1400_CR45","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/infdis\/jiad012","volume":"228","author":"C Onwuchekwa","year":"2023","unstructured":"Onwuchekwa C, Moreo LM, Menon S, et al. Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis. J Infect Dis. 2023;228(2):173\u201384.","journal-title":"J Infect Dis"},{"key":"1400_CR46","doi-asserted-by":"crossref","unstructured":"Polkowska-Kramek A, Begier E, Bruyndonckx R, et al. Estimated Incidence of Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus Infections Among Adults in Germany Between 2015 and 2019. Infectious Diseases and Therapy. 2024 2024\/04\/01;13(4):845\u2013860.","DOI":"10.1007\/s40121-024-00951-0"},{"key":"1400_CR47","doi-asserted-by":"crossref","unstructured":"Ivey KS, Edwards KM, Talbot HK. Respiratory Syncytial Virus and\u00a0Associations With Cardiovascular\u00a0Disease\u00a0in Adults. Journal of the American College of Cardiology. 2018 2018\/04\/10\/;71(14):1574\u20131583.","DOI":"10.1016\/j.jacc.2018.02.013"},{"issue":"8","key":"1400_CR48","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1164\/rccm.202308-1320OC","volume":"210","author":"DJ Wiseman","year":"2024","unstructured":"Wiseman DJ, Thwaites RS, Ritchie AI, et al. Respiratory syncytial virus-related community chronic obstructive pulmonary disease exacerbations and novel diagnostics: a binational prospective cohort study. Am J Respir Crit Care Med. 2024;210(8):994\u20131001.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1400_CR49","doi-asserted-by":"publisher","first-page":"e2511764","DOI":"10.1001\/jamanetworkopen.2025.11764","volume":"8","author":"LE Wee","year":"2025","unstructured":"Wee LE, Lim JT, Ho RWL, et al. Cardiac Events in Adults Hospitalized for Respiratory Syncytial Virus vs COVID-19 or Influenza. JAMA Netw Open. 2025;8(5):e2511764\u2013e2511764.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"1400_CR50","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jamainternmed.2024.0212","volume":"184","author":"RC Woodruff","year":"2024","unstructured":"Woodruff RC, Melgar M, Pham H, et al. Acute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus Infection. JAMA Intern Med. 2024;184(6):602\u201311.","journal-title":"JAMA Intern Med"},{"issue":"11","key":"1400_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab491","volume":"8","author":"AR Falsey","year":"2021","unstructured":"Falsey AR, Walsh EE, House S, et al. Risk factors and medical resource utilization of respiratory syncytial virus, human metapneumovirus, and influenza-related hospitalizations in adults-a global study during the 2017-2019 epidemic seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study). Open Forum Infect Dis. 2021;8(11):ofab491.","journal-title":"Open Forum Infect Dis"},{"key":"1400_CR52","unstructured":"Ubamadu E, Betancur E, Curcio D, et al. Respiratory syncytial virus sequelae among adults in high-income countries: a systematic literature review. International RSV Symposium; Belfast, UK2022."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01400-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01400-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01400-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:41:45Z","timestamp":1789245705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01400-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1400"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01400-w","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ahuva Averin, Erin Quinn, and Mark Atwood are employees of Avalere Health, which received funding from Pfizer in connection with the development of this manuscript and study. Diana Mendes is employed by Pfizer Ltd. Annefleur Langedijk and Floris van den Dungen are employed by Pfizer B.V. Frits Franssen and Marco Goeijenbier declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not require ethical approval as it does not involve any human participants, animals, or sensitive data.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}